<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174056</url>
  </required_header>
  <id_info>
    <org_study_id>DDCF-2010060</org_study_id>
    <nct_id>NCT01174056</nct_id>
  </id_info>
  <brief_title>Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging</brief_title>
  <official_title>Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to gain understanding of the basic responses of the
      lung to inflammation and specifically if a certain medication can reduce the inflammation
      alone or in combination with another. Inflammation is the way our bodies react to irritation
      or injury, and involves red, warm, and often painful swelling of the affected tissue. &quot;Acute
      lung injury&quot; involves inflammation that is not specific to one area of the lung and is caused
      by any one of several conditions: infection, trauma, breathing toxic substances, etc. When
      lung injury is severe, not enough oxygen can get into the body; this can lead to the need for
      mechanical support of breathing (mechanical ventilation), problems with brain, heart or other
      organ function, and in some cases, death.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ki, measure of FDG uptake</measure>
    <time_frame>Before and after endotoxin</time_frame>
    <description>Ki will be measured before and after endotoxin. Primary outcome measure is change in Ki (post- minus pre-endotoxin value) and absolute Ki after endotoxin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar lavage (BAL) fluid cell counts</measure>
    <time_frame>After endotoxin</time_frame>
    <description>Total and neutrophil cell counts obtained by bronchoalveolar lavage after endotoxin.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Lung Inflammation</condition>
  <arm_group>
    <arm_group_label>Pioglitazone+zileuton placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zileuton+pioglitazone placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone placebo+zileuton placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zileuton</intervention_name>
    <description>600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation</description>
    <arm_group_label>Zileuton+pioglitazone placebo</arm_group_label>
    <other_name>Zyflo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone placebo</intervention_name>
    <description>Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.</description>
    <arm_group_label>Zileuton+pioglitazone placebo</arm_group_label>
    <arm_group_label>Pioglitazone placebo+zileuton placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zileuton placebo</intervention_name>
    <description>Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.</description>
    <arm_group_label>Pioglitazone+zileuton placebo</arm_group_label>
    <arm_group_label>Pioglitazone placebo+zileuton placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>PPAR-gamma agonist</description>
    <arm_group_label>Pioglitazone+zileuton placebo</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy man or woman, any race or ethnicity, age 19 - 44 years old

          -  Screening FEV1 and FVC &gt; 90% of predicted

          -  Screening oxygen saturation by pulse oximetry &gt;97% on room air

          -  Capable of lying still and supine within the PET/CT scanner for ~1.5 hours

          -  Capable of following instructions for breathing protocol during CT portion of PET/CT

          -  Able and willing to give informed consent

          -  BMI &lt; 35

        Exclusion Criteria:

          -  Pregnancy (confirmed by qualitative urine hCG pregnancy test)

          -  Lactation

          -  Active menstruation

          -  History of cardiopulmonary disease

          -  Currently taking any prescription medications

          -  History of tobacco use or illicit drug use within the past year

          -  Presence of implanted electronic medical device

          -  Enrollment in another research study of an investigational drug

          -  Known allergy to rosiglitazone or zileuton

          -  Known allergy to both trimethoprim/sulfamethoxazole and amoxicillin

          -  Known allergy to drugs routinely used during bronchoscopy

          -  History of chronic active liver disease or acute liver disease within the past 3
             months

          -  SGOT &gt;47 IU/L, SGPT &gt; 53 IU/L, or bilirubin &gt; 1.1 mg/dl

          -  Inability lie flat for 1.5 hours for PET/CT scans or follow breathing protocol
             instructions for the CT portion of the PET/CT

          -  Prior research-related radiation exposure within the past year such that participation
             in this study would result in exposures that exceed the limits as defined by the FDA
             RDRC regulations (21 CFR 361.1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine L Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University / Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung inflammation</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>fluorodeoxyglucose</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>zileuton</keyword>
  <keyword>lung anti-inflammatory therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Zileuton</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

